The present invention provides a composition for use in the treatment of the air pollution effects on the skin or for the premature skin aging associated with the air pollution effects. The composition includes diterpenes, oleuropein, verbascoside, quercetin and hydroxytyrosol. In a preferred embodiment, the composition contains around 32% by weight of rosemary extract with a minimum diterpene content of 15% by weight, around 30% by weight of an olive fruits or leaves extract with a minimum oleuropein content of 16% by weight and a minimum hydroxytyrosol content of 5% by weight, around 28% by weight of a Lippia citriodora extract with a minimum verbascoside content of 25% by weight and around 10% by weight of a Sophora japonica extract with a minimum quercetin content of 40% by weight.

The present invention provides a composition for use in the treatment of the air pollution effects on the skin or for the premature skin aging associated with the air pollution effects. The composition includes diterpenes, oleuropein, verbascoside, quercetin and hydroxytyrosol. In a preferred embodiment, the composition contains around 32% by weight of rosemary extract with a minimum diterpene content of 15% by weight, around 30% by weight of an olive fruits or leaves extract with a minimum oleuropein content of 16% by weight and a minimum hydroxytyrosol content of 5% by weight, around 28% by weight of a Lippia citriodora extract with a minimum verbascoside content of 25% by weight and around 10% by weight of a Sophora japonica extract with a minimum quercetin content of 40% by weight.

A moisturizing lotion composition includes water. In addition, the moisturizing lotion composition includes propylene glycol having a concentration of 21.0 to 37.5 wt % of the moisturizing lotion composition. Further, the moisturizing lotion composition includes aloe vera having a concentration of 0.50 to 4.0 wt % of the moisturizing lotion composition. Still further, the moisturizing lotion composition includes vervain extract having a concentration of 0.50 to 4.0 wt % of the moisturizing lotion composition. Moreover, the moisturizing lotion composition includes willow bark extract having a concentration of 0.50 to 0.20 wt % of the moisturizing lotion composition. The moisturizing lotion composition also includes chamomilla recutita extract having a concentration of 0.05 to 0.40 wt % of the moisturizing lotion composition.

A moisturizing lotion composition includes water. In addition, the moisturizing lotion composition includes propylene glycol having a concentration of 21.0 to 37.5 wt % of the moisturizing lotion composition. Further, the moisturizing lotion composition includes aloe vera having a concentration of 0.50 to 4.0 wt % of the moisturizing lotion composition. Still further, the moisturizing lotion composition includes vervain extract having a concentration of 0.50 to 4.0 wt % of the moisturizing lotion composition. Moreover, the moisturizing lotion composition includes willow bark extract having a concentration of 0.50 to 0.20 wt % of the moisturizing lotion composition. The moisturizing lotion composition also includes chamomilla recutita extract having a concentration of 0.05 to 0.40 wt % of the moisturizing lotion composition.

The present disclosure provides a polyherbal composition for preventing and alleviating Polycystic ovary syndrome. The composition comprises an insulin regulator selected from Cinnamomum zeylyanicum and Trigonella foenum, a blood sugar regulator selected from Garcinea cambogia and Emblica officinalis, a cholesterol lowering agent selected from Linum usittatissimum and Tribulus terrestris, a prolactin regulator selected from Vitex agnus-castus and Trachyspermum ammi, a cyst shrinking component selected from Zingiber officinale and Putranjiva roxburghii, an androgen regulator selected from Ocimum sanctum, Glycyrrhiza glabra and Mentha spicate, an adrenal gland regulator selected from Withania somnifera and Sesamum indicum, an inositol containing component selected from Oryza sativa and Cicer arietinum, a binder selected from Ferula foetida and Prunus amygdalus along with a pharmaceutically acceptable excipient.

The present disclosure provides a polyherbal composition for preventing and alleviating Polycystic ovary syndrome. The composition comprises an insulin regulator selected from Cinnamomum zeylyanicum and Trigonella foenum, a blood sugar regulator selected from Garcinea cambogia and Emblica officinalis, a cholesterol lowering agent selected from Linum usittatissimum and Tribulus terrestris, a prolactin regulator selected from Vitex agnus-castus and Trachyspermum ammi, a cyst shrinking component selected from Zingiber officinale and Putranjiva roxburghii, an androgen regulator selected from Ocimum sanctum, Glycyrrhiza glabra and Mentha spicate, an adrenal gland regulator selected from Withania somnifera and Sesamum indicum, an inositol containing component selected from Oryza sativa and Cicer arietinum, a binder selected from Ferula foetida and Prunus amygdalus along with a pharmaceutically acceptable excipient.

This invention generally refers to the process to obtain a compound and a standard pharmaceutical product from one or more parts of plants of the Stachytarpheta (Verbenaceae family) species, as well as roots, stems, barks, and leaves of plants in the form of extracts or enriched fractions, or pure isolated compounds or compounds obtained from synthesis, used alone or mixed with other natural or synthetic products, in different ratios, in order to integrate pharmaceutical compositions to be used by appropriate routes (topic or oral), particularly in the form of tablets, capsules, dyes, emulsions, W/O and O/W (creams and gels), liposomes, microcapsules, nanoparticles, aerosols, ointments, and the like, as well as formulations for slow-release implants, used to treat vitiligo.

This invention generally refers to the process to obtain a compound and a standard pharmaceutical product from one or more parts of plants of the Stachytarpheta (Verbenaceae family) species, as well as roots, stems, barks, and leaves of plants in the form of extracts or enriched fractions, or pure isolated compounds or compounds obtained from synthesis, used alone or mixed with other natural or synthetic products, in different ratios, in order to integrate pharmaceutical compositions to be used by appropriate routes (topic or oral), particularly in the form of tablets, capsules, dyes, emulsions, W/O and O/W (creams and gels), liposomes, microcapsules, nanoparticles, aerosols, ointments, and the like, as well as formulations for slow-release implants, used to treat vitiligo.

This invention generally refers to the process to obtain a compound and a standard pharmaceutical product from one or more parts of plants of the Stachytarpheta (Verbenaceae family) species, as well as roots, stems, barks, and leaves of plants in the form of extracts or enriched fractions, or pure isolated compounds or compounds obtained from synthesis, used alone or mixed with other natural or synthetic products, in different ratios, in order to integrate pharmaceutical compositions to be used by appropriate routes (topic or oral), particularly in the form of tablets, capsules, dyes, emulsions, W/O and O/W (creams and gels), liposomes, microcapsules, nanoparticles, aerosols, ointments, and the like, as well as formulations for slow-release implants, used to treat vitiligo.

This invention generally refers to the process to obtain a compound and a standard pharmaceutical product from one or more parts of plants of the Stachytarpheta (Verbenaceae family) species, as well as roots, stems, barks, and leaves of plants in the form of extracts or enriched fractions, or pure isolated compounds or compounds obtained from synthesis, used alone or mixed with other natural or synthetic products, in different ratios, in order to integrate pharmaceutical compositions to be used by appropriate routes (topic or oral), particularly in the form of tablets, capsules, dyes, emulsions, W/O and O/W (creams and gels), liposomes, microcapsules, nanoparticles, aerosols, ointments, and the like, as well as formulations for slow-release implants, used to treat vitiligo.